SARMAYA THEMATIC ETF LENS 深 沪
已收盘 12-19 16:00:00 美东时间
39.0262
+0.624
+1.63%
华盛通- 最 高39.37
- 今 开39.03
- 成交量 1.44万股
- 最 低 39.0262
- 昨 收 38.4021
- 总市值 663.45万
- 52周最高 39.37
- 市盈率 静 --
- 换手率 8.48%
- 52周最低 0.32
- 委 比 -71.43%
- 总股本 17.00万
- 历史最高 39.37
- 量 比 1.24
- 振 幅 0.90%
- 历史最低 0.23
- 每 手 1
- 风险率 3.98%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immunoprecise Antibodies Announces Results Of A Newly Expanded Study Demonstrating That Its Lensai Immunogenicity Screening Can Reliably Predict Anti-Drug-Antibody Risk For Therapeutic Proteins Before They Enter Animal Studies Or Human Trials
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a Bio-Native AI pioneer operating where TechBio meets true biological intelligence, today announced results of a newly expanded study demonstrating
07-24 20:29
震撼！东大最新黑科技，要把整个美西方祖坟挖了
（转自：华山穹剑） 杭州不大，但创造的神话真的一个接一个。继人工智能DeepSeek和宇树机器人之后，杭州再次展示出一款非常重磅且足以改变世界航空产业格局的科...
07-05 20:42
ImmunoPrecise’s LENSai Platform Achieves Breakthrough in Antibody Binding Prediction
An announcement from ImmunoPrecise Antibodies ( ($IPA) ) is now available. Immu...
07-03 20:37
Welsbach Technology Metals Acquisition Corp. (“WTMA”) Announces Successful Approval for its Business Combination with Evolution Metals LLC (“EM”) from the Extraordinary General Meeting of Stockholders on June 26, 2025
<p>Welsbach Technology Metals Acquisition Corp. (WTMA) and Evolution Metals LLC (EM) have successfully merged to form Evolution Metals & Technologies Corp. (EM&T), aiming to create an independent U.S.-based supply chain for critical minerals and materials (CMM) outside of China. The combined company will list on Nasdaq under the symbol EMAT and integrate five businesses: magnet manufacturing, battery recycling, and automation design. EM&T leverag...
06-27 19:25
科技与产业动态快讯 2025年第011期
（转自：广州市工商联） 科技与产业动态快讯 2025年 第011期 目录索引： #1.首个植物功能基因组学智能问答系统PlantG...
06-26 17:40
ImmunoPrecise Confirms AI-Discovered Dengue Vaccine Target Is Safe and Triggers Immune Response
ImmunoPrecise (NASDAQ:IPA), a leader in AI-driven biotherapeutics, provides a significant update following its June 5, 2025, press release ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine
06-24 19:11
ImmunoPrecise's AI-Powered LENSai Platform, Driven By Patented HYFT Technology, Identifies A Highly Conserved Multi-Factorial Epitope Across All Four Dengue Virus Serotypes
LENSai™ powered by HYFT® technology Identifies a single multi-factorial target conserved across all dengue serotypes.ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics,
06-05 20:09
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LENSAR, Inc. announced that a majority of its independent board members granted 3,090 restricted stock units (RSUs) to 10 newly-hired non-executive employees as an inducement for joining the Company. The RSUs vest over four years, contingent on continued employment. LENSAR, a medical device company, specializes in developing advanced systems like the ALLY Robotic Cataract Laser System, which integrates AI for improved surgical outcomes and effici...
06-02 20:01
ImmunoPrecise Announces Benchmarking Results For LENSai Epitope Mapping
ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, is pleased to announce today new benchmarking results that validate the accuracy and utility of its in silico epitope mapping
05-12 20:11
Chromatin与Astellas签署合作协议
合成启动子和基因控制系统设计领域领军企业Chromatin Bioscience宣布与全球性生命科学公司Astellas Pharma达成合作协议。 根据协议...
04-15 15:53
